Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium.

J L Gabrilove; A Jakubowski; K Fain; J Grous; H Scher; C Sternberg; A Yagoda; B Clarkson; M A Bonilla; H F Oettgen

doi:10.1172/JCI113751

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York 10021.

Find articles by Gabrilove, J. in: PubMed | Google Scholar

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York 10021.

Find articles by Jakubowski, A. in: PubMed | Google Scholar

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York 10021.

Find articles by Fain, K. in: PubMed | Google Scholar

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York 10021.

Find articles by Grous, J. in: PubMed | Google Scholar

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York 10021.

Find articles by Scher, H. in: PubMed | Google Scholar

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York 10021.

Find articles by Sternberg, C. in: PubMed | Google Scholar

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York 10021.

Find articles by Yagoda, A. in: PubMed | Google Scholar

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York 10021.

Find articles by Clarkson, B. in: PubMed | Google Scholar

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York 10021.

Find articles by Bonilla, M. in: PubMed | Google Scholar

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York 10021.

Find articles by Oettgen, H. in: PubMed | Google Scholar

Published in Volume 82, Issue 4 on October 1, 1988
J Clin Invest. 1988;82(4):1454–1461. https://doi.org/10.1172/JCI113751.
© 1988 The American Society for Clinical Investigation

Published October 1, 1988 - Version history

Recombinant human granulocyte colony-stimulating factor (rhG-CSF) was administered at a dose of 1-60 micrograms/kg of body weight to 22 patients with transitional cell carcinoma before chemotherapy as part of a Phase I/II study. In all patients, a specific dose-dependent increase in the absolute neutrophil count (ANC) of 1.8-12 fold was seen. In addition, this augmentation in the ANC was accompanied by an increase in leukocyte alkaline phosphatase, a marker of secondary granule formation. In six of eight patients analyzed, an increase in bone marrow myeloid to erythroid cell ratio was seen. Day 14 peripheral blood cell derived colony forming unit granulocyte macrophage were also increased by day 6 of rhG-CSF treatment. Circulating levels of eosinophils and basophils were unchanged; however, a 10-fold increase in monocytes was observed in patients treated at the highest doses. There was also a small increase in CD3+ lymphocytes that was not dose dependent. Hemoglobin, hematocrit, and platelet count remained near baseline throughout the period of rhG-CSF administration. These findings demonstrate that rhG-CSF is a potent stimulus for normal neutrophil proliferation and maturation.

Version 1 (October 1, 1988): No description

Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium.

J L Gabrilove, A Jakubowski, K Fain, J Grous, H Scher, C Sternberg, A Yagoda, B Clarkson, M A Bonilla, and H F Oettgen

Article tools

Metrics

Go to

Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium.

J L Gabrilove, A Jakubowski, K Fain, J Grous, H Scher, C Sternberg, A Yagoda, B Clarkson, M A Bonilla, and H F Oettgen

Article tools

Metrics

Go to

Sign up for email alerts